home_page_bg.jpg

GIAPREZA

(angiotensin II) 

is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock

IMPORTANT SAFETY INFORMATION

Indication

 

GIAPREZA (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

​

Contraindications


​None.
​
Warnings and Precautions


The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.
​
Adverse Reactions

​

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.
​
Drug Interactions​


Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

​

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

 

La Jolla Pharmaceutical Company

1-800-651-3861

medicalinformation@ljpc.com

 

U.S. Food and Drug Administration

1-800-FDA-1088

www.fda.gov/medwatch

​

For additional information, please see GIAPREZA FDA prescribing information.

​

​

 Privacy Notice                    Terms of Use

LJPC logo (1).png

This site is intended for healthcare professionals in the United States

Giapreza-white.png